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Abstract
Diabetic patients who attempt strict management of blood glucose levels frequently experience hypoglycemia.
Severe and prolonged hypoglycemia causes neuronal death and cognitive impairment. There is no effective tool for
prevention of these unwanted clinical sequelae. Minocycline, a second-generation tetracycline derivative, has been
recognized as an anti-inflammatory and neuroprotective agent in several animal models such as stroke and
traumatic brain injury. In the present study, we tested whether minocycline also has protective effects on
hypoglycemia-induced neuronal death and cognitive impairment. To test our hypothesis we used an animal model
of insulin-induced acute hypoglycemia. Minocycline was injected intraperitoneally at 6 hours after hypoglycemia/
glucose reperfusion and injected once per day for the following 1 week. Histological evaluation for neuronal death
and microglial activation was performed from 1 day to 1 week after hypoglycemia. Cognitive evaluation was
conducted 6 weeks after hypoglycemia. Microglial activation began to be evident in the hippocampal area at 1 day
after hypoglycemia and persisted for 1 week. Minocycline injection significantly reduced hypoglycemia-induced
microglial activation and myeloperoxidase (MPO) immunoreactivity. Neuronal death was significantly reduced by
minocycline treatment when evaluated at 1 week after hypoglycemia. Hypoglycemia-induced cognitive impairment
is also significantly prevented by the same minocycline regimen when subjects were evaluated at 6 weeks after
hypoglycemia. Therefore, these results suggest that delayed treatment (6 hours post-insult) with minocycline
protects against microglial activation, neuronal death and cognitive impairment caused by severe hypoglycemia.
The present study suggests that minocycline has therapeutic potential to prevent hypoglycemia-induced brain
injury in diabetic patients.
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Introduction
Hypoglycemia occurs in type 1 and type 2 diabetic
patients who attempt strict management of their blood
glucose levels with insulin or other glucose-lowering drugs
[1-3]. Hypoglycemia causes recurrent morbidity in
patients, and sometimes results in mortality [4,5]. Fre-
quent low blood glucose levels in type 1 diabetic patients
can lead to the development of hypoglycemia unaware-
ness, which desensitizes patients to symptoms of low
blood glucose [6]. Hypoglycemia unawareness may lead to
prolonged nocturnal hypoglycemia, causing convulsions
and coma, and resulting in sudden death [7]. Severe
hypoglycemia, most commonly encountered in diabetic
patients who unintentionally self-administer insulin at
supratherapeutic doses, can cause potential complications
such as irritability, impaired concentration, focal neuro-
logical deficits, confusion, drowsiness, coma, seizure, and
neuronal death [8]. Under the most severe conditions,
hypoglycemic neuronal death occurs in CA1, subiculum
and dentate gyrus of the hippocampus, neurons in cortical
layers II and III of the cerebral cortex, and the dorsolateral
striatum. Hippocampal neurons are particularly important
for learning and memory, and impairment of cognitive
abilities is the most common sequelae of hypoglycemic
coma [9]. We and other groups have reported that
hypoglycemia-induced neuronal death is not a simple re-
sult of energy failure resulting from low glucose, but the
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result of activating cell death-related signaling pathways
such as glutamate receptor activation, reactive oxygen spe-
cies (ROS) production and extracellular zinc release [10-
12].
Microglia are the major innate immune cells in the
brain. Once microglia are activated by neurological dam-
age or systemic inflammatory events, activated microglia
release neurotoxic substances such as nitric oxide, ROS,
cytokines, and chemokines, and undergo morphological
changes from a ramified to an amoeboid shape [13,14].
As well, the recruitment of various types of peripherally
derived inflammatory cells such as neutrophils, T cells,
and macrophages can affect brain inflammation follow-
ing neurological damage [15]. Inhibition of inflammation
increases the rates of neuronal survival and improves
neurological deficits in several animal models of neuro-
logical injury [16,17]. Although the exact circumstances
under which microglial activation is harmful or benefi-
cial are still controversial [15], some evidence indicates
that early phase inflammation caused by acute brain in-
jury can contribute to neuronal death. In a previous
study, we showed that hypoglycemic injury-induced
microglial activation is affected by body temperature
[18]. However, it is unknown whether microglial activa-
tion is a major contributing factor in hypoglycemia-
induced neuronal death.
Minocycline is a second-generation semi-synthetic
tetracycline derivative that possesses improved tissue
penetration into the cerebrospinal fluid and the central
nervous system, compared to earlier forms. Beside the
anti-microbial effect, minocycline has anti-inflammatory
and anti-apoptotic effects. It has been shown that mino-
cycline has neuroprotective effects in animal models of
neurodegenerative disease including Parkinson’s [19],
Huntington’s [20] and Alzheimer’s disease [21], as well
as several animal models of neurological disease such as
global ischemia [22], focal cerebral ischemia [23] and
spinal cord injury [24]. These effects are thought to arise
through the inhibition of microglial activation, inducible
nitric oxide synthase, COX-2 expression or modulation
of cytokine expression. In the present study, we tested
whether delayed treatment with minocycline could also
reduce microglial activation, neuronal death and cogni-
tive impairment induced by severe hypoglycemia.
Materials and methods
Animal surgery and insulin-induced hypoglycemia
This study was approved by the San Francisco Veterans
Affairs Medical Center animal studies committee.
Hypoglycemia was induced by injection of regular
human insulin as described by Auer et al. [25] with
minor modifications [26]. Briefly, male Sprague–Dawley
rats (Charles River Laboratories, Gilroy, CA, USA)
weighing between 250 and 350 g were fasted overnight
but allowed free access to water. Hypoglycemia was
induced by intraperitoneal injection of 10 U/kg of regu-
lar insulin (Novolin-R, Novo Nordisk, Clayton, NC,
USA). The rats were anesthetized with 2% isoflurane in
a 75:25 mixture of nitrous oxide and oxygen. After tra-
cheal intubation, controlled ventilation (Harvard Appar-
atus, South Natick, MA, USA) was initiated and
anesthesia was maintained with 1% isoflurane. A 26-
gauge polyvinyl catheter was introduced into the femoral
artery for continuous arterial blood pressure monitoring
and blood sampling, and another 26-gauge polyvinyl
catheter was placed in the femoral vein for glucose infu-
sion. Cranial trephinations were performed over the bi-
lateral parietal cortex for electroencephalogram (EEG)
monitoring (BIOPAC system Inc, Santa Barbara, CA,
USA). Two monopolar electrodes were placed beneath
the dura and another reference electrode was inserted
into neck muscle. Body temperature was maintained at
36.5 to 37.5°C using a warming pad during surgery.
Hypoglycemia was terminated after 30 minutes of iso-
EEG to generate a reproducible brain injury of moderate
severity [25]. During the entire period of EEG isoelectri-
city, mean arterial blood pressure was maintained be-
tween 120 and 180 mmHg by adjusting isoflurane
concentration. Blood pressure and blood glucose levels
in animals belonging to vehicle treated and minocycline
treated group showed no difference throughout the ex-
periment (Table 1 and 2). Bradycardia and respiratory
track secretion was prevented by administration of 1
mg/kg of atropine. Hypoglycemia was terminated by ad-
ministration of 0.2 ml of 50% glucose via the femoral
vein, followed by continuous intravenous infusion of 1:1
solution of 50% glucose and Krebs-Henseleit buffer at a
rate of 1.5 ml/h for 3 hours. Rats were recovered from
anesthesia after two more hours of intravenous glucose
infusion. In sham hypoglycemia, rats were fasted over-
night and received the same dose of insulin, but were
then maintained in a normoglycemic state by intraven-
ous administration of 25% glucose (1.5 ml/3 h).
Minocycline injection
After hypoglycemic surgery or sham operation, rats in
each group were randomly assigned to two subgroups.
Minocycline (Sigma, St Louis, MO, USA) dissolved in
0.1 M phosphate buffer, pH 7.4 (50 mg/kg) or vehicle






Vehicle group (n = 6) 4.02 ± 0.13 0.40 ± 0.03 7.93 ± 0.16
Minocycline
group (n = 6)
4.08 ± 0.12 0.38 ± 0.01 7.90 ± 0.23
Iso-EEG, isoelectric electroencephalogram.
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was administered intraperitoneally once daily beginning
6 hours after glucose reperfusion for a duration of 1
week (total of seven times).
Immunohistochemistry
At the indicated time points, rats were anesthetized and
transcardially perfused with 200 ml of 0.9% saline followed
by 200 ml of 4% formaldehyde (FA). The harvested brains
were post-fixed for 24 hours and immersed in 20% su-
crose. Free-floating coronal sections (40 μm thickness)
were incubated with blocking buffer (10% goat serum and
0.1% Triton X-100 in 0.1 M PB) for 30 minutes at room
temperature. The sections were then incubated with
mouse anti-rat CD11b (1 μg/ml; Serotec, Raleigh, NC,
USA), mouse anti-NeuN (1 μg/ml; Millipore, Billerica,
MA, USA) or rabbit anti-myeloperoxidase (1:200; Thermo
scientific, Fremont, CA, USA) overnight. After washing,
the sections were incubated with biotinylated anti-mouse
or anti-rabbit IgG secondary antibody (20 μg/ml; GE
Healthcare, UK) for 2 hours. Sections were processed with
ABC reagents using a Vector ABC kit (Vector laborator-
ies, Burlingame, CA, USA). The horseradish peroxidase
reaction was detected with diaminobenzidine and H2O2.
For immunofluorescence staining, the sections were incu-
bated with Alexa Fluor 488-conjugated goat anti-mouse
IgG secondary antibody (Invitrogen, Carlsbad, CA, USA)
at a dilution of 1:500 for 2 hours at room temperature.
Negative controls performed with secondary antibody
alone showed no staining.
Assessment of neuronal survival
At 7 days and 8 weeks after hypoglycemia, rats were killed
and their brains were harvested. The sections were immu-
nostained with anti-NeuN. The number of NeuN-stained
CA1 neurons was determined in every twelfth coronal
section spanning the septal hippocampus (Bregma level
−1.8 to −3.8) using unbiased stereology (Stereo Investiga-
tor, MicroBrightField, Williston, VT, USA). A counting
frame (15 × 15 × 20 μm) was placed at the intersection of
a matrix (200 × 200 μm) randomly superimposed onto the
region of interest by the program.
Assessment of neuronal death
For identifying degenerating neurons in the hippocam-
pus, Fluoro-Jade B (FJB) staining was performed as
described previously [27]. Briefly, sections were immersed
in a basic alcohol solution for 5 minutes and 0.06%
KMnO4 for 15 minutes, and then the sections were
incubated in 0.0004% FJB (Histo-Chem, Jefferson, AR,
USA) for 20 minutes. The slides were washed in dis-
tilled water, and then dried. To quantify neuronal death,
every twelfth coronal section spanning the septal hippo-
campus (Bregma level −1.8 to −3.8) was analyzed from
each animal. A blinded observer to the minocycline
treatment condition counted the number of FJB positive
(+) neurons in the hippocampal CA1 from both hemi-
spheres. Mean counts of FJB (+) neurons from each re-
gion were used for statistical analysis.
Immunohistochemistry for evaluation of microglial
activation
CD11b immunohistochemistry was performed to deter-
mine the level of microglial activation. Microglial activa-
tion was evaluated by a blinded observer and scored
based on cell number, morphology and CD11 expression
intensity (Table 3) as modified from a previously pub-
lished method [28]. Three sections from each animal
were evaluated.
Assessment of infiltrated neutrophils
At 3 days after hypoglycemia, rats were killed and their
brains were harvested. The sections were immunostained
with anti-myeloperoxidase (anti-MPO). A blinded obser-
ver counted the number of MPO-immunopositive cells
in the cortex and hippocampus of both hemispheres.
Three sections from each animal were evaluated.
Behavioral assessments
Six weeks following the sham operation or hypoglycemia,
rats were first tested in the novel open field to evaluate
the effects of the delayed treatment with minocycline on
locomotor activity and exploratory behavior following
hypoglycemia. They were then assessed by the Barnes
maze test to evaluate spatial learning and memory [29].
In the open field test, rats were placed in a brightly lit,
square plexiglas enclosure (40 × 40 inches) surrounded
by automated infrared photocells interfaced with a
Table 2 Arterial blood pressure change before, during





Vehicle group (n = 6) 103.34 ± 1.88 185.07± 3.29 107.95 ± 3.85
Minocycline group
(n = 6)
101.91 ± 1.79 184.29± 3.13 106.44 ± 4.27
Iso-EEG, isoelectric electroencephalogram.
Table 3 Scoring for microglial activation
Score Cell number
(cell number per






0 0 0% No expression
1 1-20 1-45% Weak
2 21-40 46-90% Average
3 > 40 > 90% High
Microglia were identified by CD11b immunostaining. Scoring with three
criteria were combined to yield an aggregate microglial activation score
(0 to 9).
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computer (Hamilton Kinder, San Diego, CA, USA) to
record the data. Beam-breaks generated by movement
were monitored, allowing measurements of the number
of movements, distance moved, and time spent in the en-
closure or zones. On each of three consecutive days,
open field activity was recorded for 10 minutes after an
initial 1-minute adaptation period. For analysis of the ex-
ploratory behavior, the arena was divided on a zone map
consisting of a center region (15 × 15 inches2), four cor-
ner regions of 7.5 × 7.5 inches each, and a peripheral re-
gion (the remaining area). In the Barnes maze, a black
acrylic escape tunnel was placed under one of the holes
on a circular platform (120 cm in diameter) with 18 holes
(10 cm in diameter per hole) along the platform perim-
eter (Hamilton Kinder). The platform was elevated 60
cm above the floor. Rats from each treatment group were
randomly assigned to locate the escape tunnel from one
of the three pre-determined locations to rule out spatial
preference. Mildly noxious stimuli, blowing fans and 500
LUX of bright light, were used to increase the incentive
in finding the escape tunnel. The Noldus EthoVision
video tracking system (Noldus, Leesburg, VA, USA) was
used to record and analyze the data. Rats were trained to
locate the escape tunnel in two successive daily sessions
for 5 days (three trials per session, three minutes per
trial) with a one-hour intersession interval from different
counterbalanced starting positions.
Statistical analysis
Data are shown as means ± standard error of the mean
(SEM). Statistical significance was assessed by analysis of
variance (ANOVA) and post hoc testing was accom-
plished using the Bonferroni test. P-values less than 0.05
were considered statistically significant. Behavioral data
were evaluated by two-way repeated measures ANOVA
(RANOVA) followed by post hoc pair-wise comparisons
using the Bonferroni test. Microglial activation data were
assessed by Kruskal-Wallis non-parametric one-way
ANOVA followed by Dunn’s test for multiple group
comparison.
Results
Hypoglycemic brain injury induces microglial activation in
the brain
To characterize microglial activation following hypoglycemia,
we performed immunohistochemistry with anti-CD11b,
which detects activated microglia, at 5 days after
hypoglycemia. A substantial degree of microglial activa-
tion was detected in the hippocampus, striatum and
cerebral cortex 5 days after hypoglycemia (Figure 1). This
histological finding suggests that the inflammatory
response is involved in hypoglycemia-induced neuronal
death.
To evaluate the time-dependent activation of microglia
in the hippocampal area following hypoglycemia injury,
immunohistochemistry for CD11b was performed at the
designated time points. There was no immunoreactive
signal in the CA1 of the hippocampal area in sham-
operated animals. Microglial activation was detected
starting 1 day after the hypoglycemic insult and grad-
ually increased. At days 5 and 7 after hypoglycemia, ro-
bustly activated microglia were detected in the CA1 area
of the hippocampus (Figure 2).
Minocycline inhibits microglial activation after
hypoglycemia
In Figure 2, we show that activation of microglia appears at
24 hours after hypoglycemia in the hippocampus. In order
to test the ability of minocycline to directly prevent micro-
glial activation, (as opposed to prevention of microglial ac-
tivation via direct neuroprotection and the inhibition of
cell death signaling that might occur if treatment was
administered immediately after hypoglycemia induced-
brain damage) we injected minocycline at 6 hours after
Figure 1 Hypoglycemia induces microglial activation in the brain. Light microscopy images show microglial activation after hypoglycemia.
In the sham operated animal, CD11b-positive cells are negligible in all brain areas (Sham). However, a substantial degree of microglial activation is
detected in the hippocampus (Subiculum, CA1, and dentate gyrus (DG)), striatum (ST) and cerebral cortex (CTX) 5 days after hypoglycemia. This
histological finding suggests that the inflammatory response is involved in hypoglycemia-induced neuronal injury. Scale bar = 200 μm.
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glucose reperfusion and then once daily for 1 week. Com-
pared with the sham-operated group, hypoglycemia
increased microglial activation in the hippocampal and in
the cortical area; however, the delayed treatment with min-
ocycline reduced this activation. The number of amoeboid
cells, number of CD11b-positive cells and intensity of the
CD11b fluorescent signal was significantly reduced by min-
ocycline treatment (Figure 3).
Minocycline reduces hippocampal neuronal death after
hypoglycemia
Minocycline has been described to act as a neuroprotec-
tive agent in animal models of cerebral ischemia and
spinal cord injury. In the present study, we injected min-
ocycline at 6 hours after reperfusion to inves-
tigate its neuroprotective effect after hypoglycemia.
Immunohistochemistry with anti-NeuN was performed
to estimate the survival of CA1 neurons in the hippo-
campus. At 7 days after hypoglycemia, the NeuN-positive
CA1 layer was almost absent, compared with sham-
operated animals. But the post-treatment with minocy-
cline spared the NeuN-positive cells in the CA1 layer
(Figure 4A). Under high-magnification, the number of
NeuN-positive CA1 neurons was seen to be increased by
minocycline treatment (Figure 4B). As we counted the
number of live neurons, NeuN-positive neurons in the
CA1 area decreased in rats who experienced
hypoglycemia by about 80% compared to sham-
operated rats. However, the delayed treatment with
minocycline significantly increased the number of
NeuN-positive neurons (Figure 4C). As observed in
anti-NeuN immunohistochemistry, minocycline reduced
Figure 2 Time course of microglial activation in the hippocampal CA1 region after hypoglycemic brain injury. (A) Representative images
of microglial activation on the brain sections at indicated time points after hypoglycemic brain injury. Activated microglia were immunostained
with anti-CD11b. Scale bar = 40 μm. (B) Quantification of microglial activation in the hippocampal CA1 area of rats after hypoglycemic brain
injury. Microglial activation is scored as described in the Methods and Materials. Data are mean± standard error of the mean (SEM); #P < 0.05
compared with sham-operated animals, *P < 0.05 compared with injured animals treated with saline (n = 5).
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the degenerating cells labeled by FJB staining cells com-
pared with hypoglycemic-injured animals (Figure 4D,E).
Minocycline reduces MPO immunoreactivity induced by
hypoglycemia
It has been reported that infiltrating neutrophils contrib-
ute to neurological brain damage [30,31]. To test whether
infiltrating neutrophils are observed in hypoglycemic brain
injury and whether post-treatment with minocycline can
reduce the presence of infiltrating neutrophils, we
performed immunohistochemistry with anti-MPO to ob-
serve the degree of neutrophil infiltration in the post-
hypoglycemic hippocampus. In saline- or minocycline-
treated sham animals, MPO-positive cells were sparse in
the hippocampus. Hypoglycemic injury increased the num-
ber of infiltrating neutrophils in the CA1 pyramidal layer
and in the cortex layer II/III, an area that is vulnerable to
hypoglycemia. However, minocycline reduced neutrophilic
infiltration in the hippocampal formation, mainly in the
CA1 layer and in the cortex layer II/III (Figure 5).
Minocycline reduces motor hyperactivity caused by
hypoglycemia
To investigate whether hypoglycemia or minocycline
affects locomotor activity, rats were subjected to an open
field test at 6 weeks after hypoglycemia. All groups
were able to habituate over 3 days of testing in the
novel open field. Rats who experienced hypoglycemia
showed increased activity both horizontally and verti-
cally (Figure 6A,B; total path length: P < 0.0001; rearing:
P < 0.0001). Minocycline reduced hypoglycemia-induced
hyperactivity both horizontally (total path length;
P < 0.05) and vertically (rearing; P< 0.01).
Minocycline reduces spatial learning and memory
impairment caused by hypoglycemia
Rats were subjected to memory testing using spatial learn-
ing in the Barnes maze, a test that relies heavily on hippo-
campal function. Over the five days of training, all groups
learned the spatial task as evidenced by a progressive reduc-
tion in the distance traveled to reach the escape tunnel in
Figure 3 Minocycline reduces microglial activation after hypoglycemic brain injury. Images show that microglial activation is reduced in
the hippocampal CA1 area (CA1) (A) and in the perirhinal cortex area (Ctx) (C) by minocycline treatment after hypoglycemia. Rats received
intraperitoneal injections of saline or minocycline (MINO) at 6 hours after hypoglycemia. Injections were continued once per day for 6 days.
Microglial activation was evaluated 7 days after hypoglycemia or sham operation. Brain sections from sham-operated (Sham) or hypoglycemic-
injured (Hypoglycemia) rats were immunostained with anti-CD11b. Note that activated microglial cells, which showed amoeboid morphology
with enlarged soma and thickened processes, were reduced by the delayed treatment with minocycline. Scale bar = 40 μm. Quantification of
microglial activation in the hippocampal CA1 area (CA1) (B) and cerebral cortex (Ctx) (D) of rats receiving minocycline (MINO) or vehicle (Veh)
after hypoglycemic brain injury. Microglial activation is scored as described in the Methods and Materials. Data are mean± standard error of the
mean (SEM); *P < 0.05 compared with sham-operated animals, #P < 0.05 compared with injured animals treated with saline (Veh) (n = 6).
Won et al. Journal of Neuroinflammation 2012, 9:225 Page 6 of 12
http://www.jneuroinflammation.com/content/9/1/225
the Barnes maze (F4, 200 = 76.1, P<0.0001). Two-way
RANOVA revealed a significant effect of hypoglycemia on
spatial learning during Barnes maze acquisition
(hypoglycemia effect: F1,50 = 5.98, P<0.05). Although mino-
cycline did not have an overall effect on learning (minocy-
cline effect: F1,50 = 1.21, P>0.27), it was able to lessen the
deficit observed in the hypoglycemic (P<0.05, post hoc
test) but not in sham animals (P>0.1, post hoc test). Due
to the differential effect of minocycline on euglycemic and
hypoglycemic animals, there was a significant minocycline-
hypoglycemia interaction (F1,50 = 7.24, P<0.01) (Figure 6C).
Minocycline has a long-term protective effect on
neuronal death after hypoglycemia
To test whether the neuroprotective effect of minocy-
cline on hypoglycemia-induced neuronal death persists
for at least 8 weeks post-treatment, we killed animals
after behavioral tests and performed histochemistry to
assay neuronal viability. At 8 weeks, hippocampus that
had undergone hypoglycemic injury showed a loss of
neuronal bodies in CA1 area, but minocycline-treated
animals had more intact neuronal bodies in CA1 than
vehicle-treated ones (Figure 7).
Figure 4 Minocycline prevents hypoglycemia-induced neuronal death in the hippocampal CA1 area. (A) Representative low-magnification
images of surviving neurons in the hippocampus by minocycline treatment after hypoglycemia. Brain sections from sham-operated (Sham) or
hypoglycemia experienced (Hypoglycemia) rats were immunostained with anti-NeuN. Scale bar = 500 μm. (B) Representative high magnification
of surviving neurons in hippocampal CA1 area by minocycline treatment after hypoglycemia. Note that hypoglycemia-induced hippocampal CA1
neuronal death was protected by the delayed minocycline treatment. Scale bar = 40 μm. (C) Quantification of surviving neurons in the
hippocampal CA1 area of rats treated by minocycline (MINO) or vehicle (Veh) after hypoglycemia. Data are mean± standard error of the mean
(SEM); *P < 0.05 compared with sham-operated animals, #P < 0.05 compared with hypoglycemia animals treated with saline (Veh) (n = 6).
(D) Representative images of degenerating cells in the hippocampal CA1 area following minocycline (MINO) or saline (Vehicle) treatment after
hypoglycemia. Brain sections were stained by Fluoro-Jade B (FJB). Note that minocycline reduced the number of FJB (+) cells in the hippocampal
CA1 area after hypoglycemia. Scale bar = 40 μm. (E) Quantification of Fluoro-Jade B (+) cells in the hippocampal CA1 area from rats treated with
minocycline after hypoglycemia. Data are mean± SEM; *P < 0.05 compared with hypoglycemia-subjected rats treated with saline (n = 6).
Won et al. Journal of Neuroinflammation 2012, 9:225 Page 7 of 12
http://www.jneuroinflammation.com/content/9/1/225
Discussion
The present study shows that delayed treatment with min-
ocycline reduces microglial activation and neuronal death
in the hippocampus after hypoglycemia. Minocycline
treatment also prevented cognitive impairment at later
time points. These results suggest that minocycline is an
effective therapeutic candidate to prevent neuronal death
and subsequent cognitive impairment after hypoglycemia.
The mechanisms of hypoglycemia-induced neuronal in-
jury represent a more complex process than a simple lack
of glucose supply to the brain [32,33]. Rather, several con-
tributing factors are involved in downstream events of
hypoglycemia-induced neuronal death such as sustained
activation of glutamate receptors [10], poly(ADP-ribose)
polymerase activation [26], zinc translocation [11] and
NADPH oxidase activation [12]. Although several studies
have been reported to intervene in this neuronal death
cascade, there is currently no clinically applicable inter-
vention strategy available. Therefore, this study has
sought an indirect intervention strategy for preventing
hypoglycemia-induced neuronal death and cognitive im-
pairment that may be more clinically relevant.
The brain injury produced by hypoglycemia maturates
over a period of several hours or days as seen in ischemia
[34]. Especially in hypoglycemia, delayed hippocampal
damage is observed 3 to 5 days after the insult in CA1
pyramidal neurons [35], suggesting that mechanisms that
develop slowly after hypoglycemia have a role in
hypoglycemic neuronal death. Recent studies have shown
that inflammatory cells infiltrate the ischemic area [36] or
the hypoglycemic brain area [18]. Inflammation is now
recognized as a significant contributing mechanism in
cerebral ischemia because anti-inflammatory compounds
or inhibitors of iNOS and cyclooxygenase-2 reduce ische-
mic damage and improve the outcome of animals after is-
chemic insult [37,38].
Microglial activation contributes to ischemia and trau-
matic brain injury-induced neuronal death. Previously
Figure 5 Minocycline reduces myeloperoxidase (MPO) immunoreactivity induced by hypoglycemia in the hippocampus. Representative
images of reduction in MPO immunoreactive cells in the hippocampal CA1 area (CA1) (A) and in the perirhinal cortex (Ctx) (C) by minocycline
treatment after hypoglycemia. Note that hypoglycemia-induced MPO-positive infiltrating cells were reduced by the delayed minocycline
treatment. Scale bar = 40 μm. Quantification of MPO-positive cells in the hippocampus (CA1) (B) and in the cortex (Ctx) (D ) of rats treated with
minocycline (MINO) or saline (Vehicle) after hypoglycemia. The number of MPO (+) cells was counted under microscope as described in Methods
and Materials. Data are mean± standard error of the mean (SEM); *P < 0.05 compared with sham-operated animals, #P < 0.05 compared with
hypoglycemia animals treated with saline (Vehicle) (n = 7).
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our lab showed microglia are activated after hypoglycemia
[39]. Microglia are the major innate immune cells resi-
dent in the brain. Once activated by neurological damage
or systemic inflammatory events, microglia release neuro-
toxic substances such as nitric oxide, ROS, cytokines, and
chemokines, and undergo morphological change from a
ramified to an amoeboid shape [13,14]. Whether micro-
glial activation is a net harmful or beneficial process is
still controversial [15], however, there is evidence that
indicates that early phage inflammation by acute brain in-
jury can contribute to neuronal death. Our previous study
shows that hypoglycemia induces microglial activation in
the brain, which is affected by body temperature and ves-
icular zinc release [18]. However, it is unknown whether
the prevention of microglial activation by minocycline
after hypoglycemia is neuroprotective.
Infiltrating peripheral inflammatory cells play import-
ant roles in the development of pathophysiological re-
sponse following neurological damage. Brain damage,
such as ischemic or traumatic injury, triggers physio-
logical changes and neuronal death that induces adhe-
sion of circulating leukocytes, leading to their migration
into brain, causing release of pro-inflammatory sub-
stances [17,40]. MPO produced from neutrophils has
been used as a marker of infiltrating neutrophils and is
involved in brain damage following such events as trau-
matic brain injury and cerebral ischemia. Numerous
studies have been reported in which the accumulation of
MPO-positive neutrophils into the ischemic brain is cor-
related with ischemic brain damage, although MPO gene
deletion has been shown to exacerbate brain injury,
which is mediated by the peroxynitrite reaction but not
MPO [31,41]. Activation of microglia precedes neutro-
phil infiltration and seems to play a role in the recruit-
ment of neutrophils following brain damage [42]. In our
study, the MPO-positive neutrophils were observed in
the hippocampal formation following hypoglycemic
brain injury and this recruitment was prevented by
Figure 6 Minocycline reduces motor hyperactivity and cognitive impairment induced by hypoglycemia. Six weeks after induction of
hypoglycemia, rats were subjected to a 3-day novel open field test followed by the Barnes maze test. Four groups of animals were divided for
behavioral testing as follows: sham+Vehicle; sham+minocycline (MINO); hypoglycemia + Vehicle; and hypoglycemia +minocycline (MINO)
groups. Minocycline reduced overall hyperactivity induced by hypoglycemia in both horizontal and vertical dimensions as shown in total path
length (A) and rearing events (B). Minocycline also improved the performance of rats with hypoglycemia in the Barnes maze test over 5 days of
training (C). *P< 0.05, # P < 0.01 comparing HG+ Vehicle and HG+MINO groups.
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minocycline. It suggests that neutrophil infiltration may
be involved in brain inflammation and neuronal death
after hypoglycemic injury and may be prevented by min-
ocycline treatment.
Although minocycline was developed as an anti-
microbial drug for the treatment of various infectious dis-
eases, many other functions such as anti-apoptotic and
anti-inflammatory effects have been identified [43]. In
particular the anti-inflammatory properties of minocy-
cline have been observed in acute and chronic neuro-
logical disease animal models, as well as in human
clinical trial studies [22,23,44]. In an animal model of
multiple sclerosis, minocycline decreased the transmigra-
tion of T lymphocytes and inhibited the activation of
metalloproteinases that degrade the extracellular matrix
proteins of the basal lamina surrounding blood vessels,
causing neutrophil infiltration [45,46]. Based on these
studies, our present results suggest that delayed treatment
with minocycline can have a neuroprotective effect on
hypoglycemic neuronal death by inhibiting microglial ac-
tivation and neutrophil infiltration.
Since most hypoglycemic patients visit the emergency
room several hours after the hypoglycemic episode, we
delivered the initial dose of minocycline 6 hours after
hypoglycemic insult. Microglial activation was detected
in the hippocampus 24 hours after hypoglycemia. Thus
we believe that treatment of 6-hours post-hypogecemic
insult is a reasonable therapeutic window. Although we
injected minocycline from 6 hours after hypoglycemia,
microglial activation was significantly reduced, as was
neuronal death. These results suggest that delayed treat-
ment with minocycline suppressed microglial activation,
which may decrease release of toxic substances such as
nitric oxide, and IL6, etcetera. This further suggests that
acute microglial activation after hypoglycemia is detri-
mental to neuronal survival.
Since minocycline is one of the most lipid-soluble
tetracycline-class antibiotics, it can easily penetrate into
the brain. Minocycline also has a long half-life compared
to other tetracycline antibiotics [47]. Thus, one or two
doses of 50 to 100 mg per day of minocycline are effect-
ive in many patients to treat bacterial infection. A recent
clinical study found that patients who received 200 mg
of minocycline for five days within 24 hours after ische-
mic stroke showed significantly better outcome com-
pared with patients receiving placebo [48]. In the
present study, we used 50 mg/kg per day for one week
in rats. We understand that this concentration of mino-
cycline is fairly high for a single dose. Therefore, for
clinical applications, a single dose of minocycline for
prevention of hypoglycemia-induced neuronal death
should be re-evaluated.
Learning and memory deficits are common neurological
sequelae following hypoglycemia in patients with type 1
diabetes and in the relatively younger population with type
2 diabetes [49-51]. Our previous study showed that
hypoglycemia-induced hippocampal damage induced im-
pairment of learning and memory [26]. In the present
study, the Barnes maze test was performed to evaluate
spatial learning and memory. As seen in our previous
study using the water maze test, subjects experiencing se-
vere hypoglycemia displayed a longer distance traveled to
reach the escape tunnel, implying that spatial learning has
been compromised. However, minocycline treatment
reduced the travel distance in rats who experienced
Figure 7 Delayed treatment with minocycline has long-term
protective effects after hypoglycemia. (A) Representative images
of surviving neurons in the post-hypoglycemic hippocampal CA1
area following minocycline treatment. Note that hypoglycemia-
induced hippocampal CA1 neuronal death was protected by the
delayed minocycline treatment 8 weeks after hypoglycemia. Scale
bar = 80 μm. (B) Quantification of surviving neurons in the
hippocampal CA1 area of rats treated with minocycline (MINO) or
saline (Veh) 8 weeks after hypoglycemia. The number of neurons
was counted using the stereology method as described in Methods
and Materials. Data are mean± standard error of the mean (SEM);
*P < 0.05 compared with sham-operated animals treated with saline
(Veh), #P < 0.05 compared with hypoglycemia animals treated with
saline (n = 6).
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hypoglycemia. It has been reported that minocycline
improves cognitive impairment in focal cerebral ischemia
[52], Alzheimer’s disease models [53], and other animal
models of neurological disease [54,55].
Because tetracycline derivatives, like minocycline, have
anti-inflammatory properties and are clinically well tol-
erated, we studied whether minocycline could serve as
a neuroprotective compound against hypoglycemia-
induced brain injury. In the present study, we report that
in a rat model of hypoglycemia, 1) minocycline is neuro-
protective, even when the treatment is initiated 6 hours
after hypoglycemia; 2) minocycline prevents microglial
activation after hypoglycemia; and 3) minocycline pre-
vents cognitive impairment even at several weeks after
hypoglycemia. Thus, the present study suggests that pre-
vention of microglial activation by minocycline has a
strong therapeutic potential for prevention of
hypoglycemia-induced brain injury.
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